Tempus AI Target of Unusually Large Options Trading (NASDAQ:TEM)
by Doug Wharley · The Cerbat GemTempus AI, Inc. (NASDAQ:TEM – Get Free Report) was the target of some unusual options trading on Wednesday. Stock traders acquired 32,895 call options on the stock. This represents an increase of approximately 68% compared to the average volume of 19,625 call options.
Analyst Upgrades and Downgrades
Several research firms recently commented on TEM. JPMorgan Chase & Co. cut their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. TD Cowen raised Tempus AI from a “hold” rating to a “buy” rating and set a $65.00 price target for the company in a report on Monday. BTIG Research cut their price target on Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Stifel Nicolaus set a $60.00 price target on Tempus AI in a report on Wednesday, February 25th. Finally, Canaccord Genuity Group cut their price target on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.36.
View Our Latest Research Report on Tempus AI
More Tempus AI News
Here are the key news stories impacting Tempus AI this week:
- Positive Sentiment: Announced a commercial expansion with Predicta Biosciences for a co-branded whole‑genome sequencing assay (GenoPredicta) aimed at deeper genomic characterization and MRD monitoring — strengthens Tempus’ diagnostics product set and commercial footprint in hematologic oncology. Tempus and Predicta Biosciences Announce Collaboration
- Positive Sentiment: Launched an automated “Active Follow‑Up” workflow to keep therapy guidance current for oncology providers — a product feature that can increase clinical stickiness of Tempus’ Hub platform and reduce report obsolescence risk. Tempus Launches Automated “Active Follow-Up” Service
- Positive Sentiment: Company will present 31 abstracts (including one oral) at AACR 2026 — new data visibility at a major oncology conference can help validate Tempus’ multimodal dataset and drive commercial/partnership interest. Tempus Announces 31 Abstracts for AACR 2026
- Positive Sentiment: TD Cowen upgraded Tempus to a Buy — an analyst upgrade adds buy‑side visibility and can support near‑term demand. Tempus AI Raised to “Buy” at TD Cowen
- Positive Sentiment: Mizuho reconfirmed a Buy rating — additional supportive analyst coverage helps sustain investor interest. Mizuho Keeps Buy Rating on Tempus
- Positive Sentiment: Management visibility at the Needham Virtual Healthcare Conference and related investor materials/press coverage boosted attention and trading interest. Needham Conference Presentation Transcript
- Neutral Sentiment: Collaboration with One‑Carbon Therapeutics announced — expands research partnerships but is likely more R&D‑focused near term. One‑Carbon Therapeutics Collaboration
- Negative Sentiment: Jefferies initiated coverage with an Underperform/negative view — a new sell/underperform initiation can pressure sentiment despite other positive headlines. Jefferies Initiates Coverage with Underperform
- Negative Sentiment: Significant insider selling noted in recent months (multiple executive sales) — heavy insider dispositions can weigh on investor perceptions of insider alignment. QuiverQuant Coverage (insider activity & product updates)
Insiders Place Their Bets
In other news, EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.43, for a total value of $562,445.52. Following the transaction, the executive vice president owned 79,816 shares in the company, valued at $4,743,464.88. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $566,407.60. Following the completion of the sale, the chief executive officer directly owned 694,354 shares of the company’s stock, valued at approximately $41,001,603.70. This represents a 1.36% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 563,841 shares of company stock valued at $32,258,311. 26.27% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Tempus AI
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after acquiring an additional 817,014 shares during the last quarter. ARK Investment Management LLC boosted its position in shares of Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after buying an additional 381,816 shares during the period. GC Wealth Management RIA LLC purchased a new position in shares of Tempus AI during the fourth quarter worth $399,267,000. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Tempus AI by 1.2% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company’s stock worth $206,960,000 after buying an additional 41,728 shares during the period. Finally, Amova Asset Management Americas Inc. boosted its position in shares of Tempus AI by 1.2% during the fourth quarter. Amova Asset Management Americas Inc. now owns 3,504,823 shares of the company’s stock worth $206,960,000 after buying an additional 41,728 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.
Tempus AI Trading Up 9.8%
TEM stock traded up $4.87 during midday trading on Wednesday, hitting $54.40. 7,333,329 shares of the company’s stock were exchanged, compared to its average volume of 5,408,844. The business has a 50-day simple moving average of $50.72 and a two-hundred day simple moving average of $66.35. The company has a current ratio of 3.13, a quick ratio of 3.00 and a debt-to-equity ratio of 2.52. The stock has a market capitalization of $9.73 billion, a PE ratio of -38.71 and a beta of 4.90. Tempus AI has a 1-year low of $39.01 and a 1-year high of $104.32.
About Tempus AI
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.